Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands

Pharmaceutical Research

Volumn 23, Issue 8, 2006, Pages 1641-1658

  Gao, Wenqing ^a   Kim, Juhyun ^a   Dalton, James T ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b LM Parks Hall ^*  (United States)

^c GTx Inc   (United States)

Author keywords

Androgen receptor; Antiandrogen; Pharmacokinetics; Prostate cancer; Selective androgen receptor modulator; Testosterone

Indexed keywords

2 HYDROXYFLUTAMIDE; 4 [3 (4 HYDROXYBUTYL) 4,4 DIMETHYL 2,5 DIOXO 1 IMIDAZOLIDINYL] 2 TRIFLUOROMETHYLBENZONITRILE; ANABOLIC AGENT; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; BMS 25; BMS 564929; BMS 7; BMS 9; FLUTAMIDE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDANTOIN DERIVATIVE; LG 105; LG 120907; LIGAND; NANDROLONE DECANOATE; NILUTAMIDE; NONSTEROIDAL ANDROGEN RECEPTOR LIGAND; OXANDROLONE; PROPIONAMIDE DERIVATIVE; QUINONE DERIVATIVE; RU 58624; RU 58642; S 40503; SELECTIVE ANDROGEN RECEPTOR MODULATOR; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ALOPECIA; ANEMIA; CACHEXIA; CLINICAL TRIAL; CONTRACEPTION; DRUG METABOLISM; FRAIL ELDERLY; GYNECOMASTIA; HIRSUTISM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPOGONADISM; IMPOTENCE; LIBIDO DISORDER; LIVER TOXICITY; MUSCLE ATROPHY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; WITHDRAWAL SYNDROME;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANIMALS; FEMALE; HUMANS; LIGANDS; MALE; RECEPTORS, ANDROGEN; STEROIDS;

EID: 33746894825     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9024-3     Document Type: Review

References (77)

1. W. Gao, C. E. Bohl, and J. T. Dalton. Chemistry and structural biology of androgen receptor. Chem. Rev. 105:3352-3370 (2005).
2. R. C. Buijsman, P. H. Hermkens, R. D. van Rijn, H. T. Stock, and N. M. Teerhuis. Non-steroidal steroid receptor modulators. Curr. Med. Chem. 12:1017-1075 (2005).
3. J. Chen, J. Kim, and J. T. Dalton. Discovery and therapeutic promise of selective androgen receptor modulators. Mol. Interv. 5:173-188 (2005).
4. S. Venturoli, O. Marescalchi, F. M. Colombo, S. Macrelli, B. Ravaioli, A. Bagnoli, R. Paradisi, and C. Flamigni. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 84:1304-1310 (1999).
5. E. T. Keller, W. B. Ershler, and C. Chang. The androgen receptor: a mediator of diverse responses. Front Biosci. 1:d59-d71 (1996).
6. L. S. Goodman, J. G. Hardman, L. E. Limbird, and A. G. Gilman. Goodman & Gilman's the Pharmacological Basis of Therapeutics, McGraw-Hill Medical Pub. Division, New York, 2001.
7. K. L. Johansen. Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin. Dial. 17:202-208 (2004).
8. M. Oettel. Testosterone metabolism, dose-response relationships and receptor polymorphisms: selected pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men. Aging Male 6:230-256 (2003).
9. M. Oettel. Is there a role for estrogens in the maintenance of men's health? Aging Male 5:248-257 (2002).
10. W. Rondede, H. A. Pols, J. P. van Leeuwen, and F. H. de Jong The importance of oestrogens in males Jongde. Clin. Endocrinol. (Oxf) 58:529-542 (2003).
11. E. Barrett-Connor, D. Goodman-Gruen, and B. Patay. Endogenous sex hormones and cognitive function in older men. J. Clin. Endocrinol. Metab. 84:3681-3685 (1999).
12. I. Van Pottelbergh, L. Braeckman, D. De Bacquer, G. De Backer, and J. M. Kaufman. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166:95-102 (2003).
13. T. K. Mukherjee, H. Dinh, G. Chaudhuri, and L. Nathan. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc. Natl. Acad. Sci. USA 99:4055-4060 (2002).
14. K. Toda, T. Okada, K. Takeda, S. Akira, T. Saibara, M. Shiraishi, S. Onishi, and Y. Shizuta. Oestrogen at the neonatal stage is critical for the reproductive ability of male mice as revealed by supplementation with 17beta-oestradiol to aromatase gene (Cyp19) knockout mice. J. Endocrinol. 168:455-463 (2001).
15. A. Falahati-Nini, B. L. Riggs, E. J. Atkinson, W. M. O'Fallon, R. Eastell, and S. Khosla. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 106:1553-1560 (2000).
16. E. S. Orwoll. Men, bone and estrogen: unresolved issues. Osteoporos. Int. 14:93-98 (2003).
17. A. E. Thigpen, R. I. Silver, J. M. Guileyardo, M. L. Casey, J. D. McConnell, and D. W. Russell. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J. Clin. Invest 92:903-910 (1993).
18. A. M. Isidori, E. A. Greco, and A. Aversa. Androgen deficiency and hormone-replacement therapy. BJU Int. 96:212-216 (2005).
19. H. Fang, W. Tong, W. S. Branham, C. L. Moland, S. L. Dial, H. Hong, Q. Xie, R. Perkins, W. Owens, and D. M. Sheehan. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem. Res. Toxicol. 16:1338-1358 (2003).
20. W. R. Kelce, E. Monosson, M. P. Gamcsik, S. C. Laws, and L. E. Gray Jr. Environmental hormone disruptors: evidence that vinclozolin developmental toxicity is mediated by antiandrogenic metabolites. Toxicol. Appl. Pharmacol. 126:276-285 (1994).
21. C. L. Waller, B. W. Juma, L. E. Gray Jr., and W. R. Kelce. Three-dimensional quantitative structure-activity relationships for androgen receptor ligands. Toxicol. Appl. Pharmacol. 137:219-227 (1996).
22. A. E. Wakeling, B. J. Furr, A. T. Glen, and L. R. Hughes. Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens. J. Steroid Biochem. 15:355-359 (1981).
23. M. Schulz, A. Schmoldt, F. Donn, and H. Becker. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur. J. Clin. Pharmacol. 34:633-636 (1988).
24. B. Katchen and S. Buxbaum. Disposition of a new, nonsteroid, antiandrogen, alpha,alpha,alpha-trifluoro-2-methyl-4′-nitro-m- propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J. Clin. Endocrinol. Metab. 41:373-379 (1975).
25. D. Fau, D. Eugene, A. Berson, P. Letteron, B. Fromenty, C. Fisch, and D. Pessayre. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J. Pharmacol. Exp. Ther. 269:954-962 (1994).
26. P. J. Creaven, L. Pendyala, and D. Tremblay. Pharmacokinetics and metabolism of nilutamide. Urology 37:13-19 (1991).
27. A. Berson, C. Wolf, V. Berger, D. Fau, C. Chachaty, B. Fromenty, and D. Pessayre. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. J. Pharmacol. Exp. Ther. 257:714-719 (1991).
28. D. Fau, A. Berson, D. Eugene, B. Fromenty, C. Fisch, and D. Pessayre. Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J. Pharmacol. Exp. Ther. 263:69-77 (1992).
29. I. D. Cockshott. Bicalutamide: clinical pharmacokinetics and metabolism. Clin. Pharmacokinet. 43:855-878 (2004).
30. G. W. Boyle, D. McKillop, P. J. Phillips, J. R. Harding, R. Pickford, and A. D. McCormick. Metabolism of Casodex in laboratory animals. Xenobiotica 23:781-798 (1993).
31. D. McKillop, G. W. Boyle, I. D. Cockshott, D. C. Jones, P. J. Phillips, and R. A. Yates. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 23:1241-1253 (1993).
32. P. Schellhammer, R. Sharifi, N. Block, M. Soloway, P. Venner, A. L. Patterson, M. Sarosdy, N. Vogelzang, J. Jones, and G. Kolvenbag. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 45:745-752 (1995).
33. B. J. Furr and H. Tucker. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47:13-25;discussion 29-32 (1996).
34. M. Lefort, M. Diaz Curiel, M. T. Carrascal, C. Mendez-Davila, and C. de la Piedra. Comparative effects of bicalutamide (Casodex) versus orchidectomy on bone mineral density, bone remodelling, and bone biomechanics in healthy rats. Urol. Int. 74:301-307 (2005).
35. T. Battmann, C. Branche, F. Bouchoux, E. Cerede, D. Philibert, F. Goubet, G. Teutsch, and M. Gaillard-Kelly. Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders. J. Steroid Biochem. Mol. Biol. 64:103-111 (1998).
36. M. E. Taplin, B. Rajeshkumar, S. Halabi, C. P. Werner, B. A. Woda, J. Picus, W. Stadler, D. F. Hayes, P. W. Kantoff, N. J. Vogelzang, and E. J. Small. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol. 21:2673-2678 (2003).
37. H. Suzuki, K. Akakura, A. Komiya, S. Aida, S. Akimoto, and J. Shimazaki. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29:153-158 (1996).
38. T. Hara, J. Miyazaki, H. Araki, M. Yamaoka, N. Kanzaki, M. Kusaka, and M. Miyamoto. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63:149-153 (2003).
39. T. Yoshida, H. Kinoshita, T. Segawa, E. Nakamura, T. Inoue, Y. Shimizu, T. Kamoto, and O. Ogawa. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 65:9611-9616 (2005).
40. M. E. Salvati, M. Gottardis, S. R. Krystek, R. M. Attar, and J. Sack. Selective androgen receptor modulators and methods for their identification, design, and use, Patent WO0200617, 2002.
41. M. E. Salvati, A. Balog, W. Shan, D. D. Wei, D. Pickering, R. M. Attar, J. Geng, C. A. Rizzo, M. M. Gottardis, R. Weinmann, S. R. Krystek, J. Sack, Y. An, and K. Kish. Structure based approach to the design of bicyclic-1H- isoindole-1,3(2H)-dione based androgen receptor antagonists. Bioorg. Med. Chem. Lett. 15:271-276 (2005).
42. M. E. Van Dort and Y. W. Jung. Synthesis and structure-activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands. Bioorg. Med. Chem. Lett. 11:1045-1047 (2001).
43. T. Battmann, A. Bonfils, C. Branche, J. Humbert, F. Goubet, G. Teutsch, and D. Philibert. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J. Steroid Biochem. Mol. Biol. 48:55-60 (1994).
44. D. Cousty-Berlin, B. Bergaud, M. C. Bruyant, T. Battmann, C. Branche, and D. Philibert. Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. J. Steroid Biochem. Mol. Biol. 51:47-55 (1994).
45. L. G. Hamann, R. I. Higuchi, L. Zhi, J. P. Edwards, X. N. Wang, K. B. Marschke, J. W. Kong, L. J. Farmer, and T. K. Jones. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J. Med. Chem. 41:623-639 (1998).
46. L. Zhi and E. Martinborough. Selective androgen receptor modulators (SARMs). Annual Reports of Medicinal Chemistry 36:169-180 (2001).
47. A. Negro-Vilar. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 84:3459-3462 (1999).
48. L. G. Hamann, N. S. Mani, R. L. Davis, X. N. Wang, K. B. Marschke, and T. K. Jones. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). J. Med. Chem. 42:210-212 (1999).
49. J. Rosen and A. Negro-Vilar. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J. Musculoskelet. Neuronal. Interact. 2:222-224 (2002).
50. C. E. Bohl, C. Chang, M. L. Mohler, J. Chen, D. D. Miller, P. W. Swaan, and J. T. Dalton. A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J. Med. Chem. 47:3765-3776 (2004).
51. L. Zhi, C. M. Tegley, K. B. Marschke, and T. K. Jones. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. Bioorg. Med. Chem. Lett. 9:1009-10012 (1999).
52. D. Yin, W. Gao, J. D. Kearbey, H. Xu, K. Chung, Y. He, C. A. Marhefka, K. A. Veverka, D. D. Miller, and J. T. Dalton. Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 304:1334-1340 (2003).
53. W. Gao, J. D. Kearbey, V. A. Nair, K. Chung, A. F. Parlow, D. D. Miller, and J. T. Dalton. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 145:5420-5428 (2004).
54. W. Gao, P. J. Reiser, C. C. Coss, M. A. Phelps, J. D. Kearbey, D. D. Miller, and J. T. Dalton. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146:4887-4897 (2005).
55. J. D. Kearbey, W. Gao, D. D. Miller, and J. T. Dalton. Selective androgen receptor modulators inhibit bone resorption in rats. AAPS PharmSci. 5:(2003).
56. J. Chen, D. J. Hwang, C. E. Bohl, D. D. Miller, and J. T. Dalton. A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. 312:546-553 (2005).
57. J. Kim, D. Wu, D. J. Hwang, D. D. Miller, and J. T. Dalton. The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl- phenyl)-prop ionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 315:230-239 (2005).
58. J. D. Kearbey, D. Wu, W. Gao, D. D. Miller, and J. T. Dalton. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3- trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica 34:273-280 (2004).
59. W. Gao, J. S. Johnston, D. D. Miller, and J. T. Dalton. Inter-Species Differences in Pharmacokinetics and Metabolism of S-3-(4-acetylamino-phenoxy)-2- hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide: the role of N-Acetyltransferase. Drug. Metab. Dispos. (2005).
60. W. Gao, Z. Wu, C. E. Bohl, J. Yang, D. D. Miller, and J. T. Dalton. Characterization of the in vitro metabolism of selective androgen receptor modulator (SARM) using human, rat and dog liver enzyme preparations. Drug Metab. Dispos. (2005).
61. W. Gao, Z. Wu, K. Chung, D. D. Miller, and J. T. Dalton. Phase I Metabolism Study of Selective Androgen Receptor Modulators (SARMs) with human liver microsomes. AAPS PharmSci. 5 (2003).
62. D. Yin, Y. He, M. A. Perera, S. S. Hong, C. Marhefka, N. Stourman, L. Kirkovsky, D. D. Miller, and J. T. Dalton. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. 63:211-223 (2003).
63. J. Chen, D. J. Hwang, K. Chung, C. E. Bohl, S. J. Fisher, D. D. Miller, and J. T. Dalton. In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology 146:5444-5454 (2005).
64. C. A. Marhefka, W. Gao, K. Chung, J. Kim, Y. He, D. Yin, C. Bohl, J. T. Dalton, and D. D. Miller. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. 47:993-998 (2004).
65. C. E. Bohl, D. D. Miller, J. Chen, C. E. Bell, and J. T. Dalton. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. 280:37747-37754 (2005).
66. C. E. Bohl, W. Gao, D. D. Miller, C. E. Bell, and J. T. Dalton. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. USA 102:6201-6206 (2005).
67. L. G. Hamann. Discovery and preclinical profile of a highly potent and muscle selective androgen receptor modulator (SARM). 227th National Meeting of the American Chemical Society Medicinal Chemistry Division (2004).
68. K. Hanada, K. Furuya, N. Yamamoto, H. Nejishima, K. Ichikawa, T. Nakamura, M. Miyakawa, S. Amano, Y. Sumita, and N. Oguro. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. 26:1563-1569 (2003).
69. M. Miyakawa, N. Oguro, K. Hanada, K. Furuya, and N. Yamamoto. Preparation of novel tetrahydroquinoline derivatives as androgen receptor agonists, Patent WO 2004013104, 2004.
70. H. Gronemeyer, J. A. Gustafsson, and V. Laudet. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3:950-964 (2004).
71. C. L. Smith and B. W. O'Malley. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25:45-71 (2004).
72. B. S. Katzenellenbogen and J. A. Katzenellenbogen. Biomedicine. Defining the "S" in SERMs. Science 295:2380-2381 (2002).
73. R. G. Christiansen, M. R. Bell, T. E. D'Ambra, J. P. Mallamo, J. L. Herrmann, J. H. Ackerman, C. J. Opalka, R. K. Kullnig, R. C. Winneker, and B. W. Snyder et al. Antiandrogenic steroidal sulfonylpyrazoles. J. Med. Chem. 33:2094-2100 (1990).
74. I. D. Cockshott, G. F. Plummer, K. J. Cooper, and M. J. Warwick. The pharmacokinetics of Casodex in laboratory animals. Xenobiotica 21:1347-1355 (1991).
75. J. P. Edwards, R. I. Higuchi, T. K. Jones, and L. G. Hamann. Androgen receptor modulator compounds and methods, Patent US6017924, Ligand Pharmaceuticals Incorporated, United States, 2000.
76. G. F. Allan, and Z. Sui. Therapeutic androgen receptor ligands. NURSA e-Journal 1: ID# 3.09172003.1 (2003).
77. L. Zhi, C. M. Tegley, B. Pio, V. O. C. Arjan, M. Motamedi, E. Martinborough, S. West, R. I. Higuchi, L. G. Hamann, and L. J. Farmer. Bicyclic androgen and progesterone receptor modulator compounds and methods, Patent WO0116108, 2001.